IRIS Accounts Production v24.2.0.383 11905461 director 1.1.23 31.12.23 31.12.23 26.9.2024 false true false false true false Auditors Opinion Ordinary. 0.0100 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh119054612022-12-31119054612023-12-31119054612023-01-012023-12-31119054612021-12-31119054612022-01-012022-12-31119054612022-12-3111905461ns15:EnglandWales2023-01-012023-12-3111905461ns14:PoundSterling2023-01-012023-12-3111905461ns10:Director12023-01-012023-12-3111905461ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3111905461ns10:SmallEntities2023-01-012023-12-3111905461ns10:Audited2023-01-012023-12-3111905461ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3111905461ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3111905461ns10:FullAccounts2023-01-012023-12-3111905461ns10:OrdinaryShareClass22023-01-012023-12-3111905461ns10:RegisteredOffice2023-01-012023-12-3111905461ns5:CurrentFinancialInstruments2023-12-3111905461ns5:CurrentFinancialInstruments2022-12-3111905461ns5:ShareCapital2023-12-3111905461ns5:ShareCapital2022-12-3111905461ns5:RetainedEarningsAccumulatedLosses2023-12-3111905461ns5:RetainedEarningsAccumulatedLosses2022-12-3111905461ns5:PlantMachinery2023-01-012023-12-3111905461ns5:PlantMachinery2023-12-3111905461ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3111905461ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3111905461ns5:WithinOneYear2023-12-3111905461ns5:WithinOneYear2022-12-3111905461ns10:OrdinaryShareClass22023-12-31
REGISTERED NUMBER: 11905461 (England and Wales)





FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST DECEMBER 2023

FOR

IGES UK PHARMA CONSULTING LTD

IGES UK PHARMA CONSULTING LTD (REGISTERED NUMBER: 11905461)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST DECEMBER 2023










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


IGES UK PHARMA CONSULTING LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31ST DECEMBER 2023







DIRECTOR: B K Haeussler





REGISTERED OFFICE: 25 St Thomas Street
Winchester
Hampshire
SO23 9HJ





REGISTERED NUMBER: 11905461 (England and Wales)





AUDITORS: Martin and Company
Audit Limited
25 St Thomas Street
Winchester
Hampshire
SO23 9HJ

IGES UK PHARMA CONSULTING LTD (REGISTERED NUMBER: 11905461)

BALANCE SHEET
31ST DECEMBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,849 -

CURRENT ASSETS
Debtors 5 52,312 12,707
Cash at bank 111,828 12,665
164,140 25,372
CREDITORS
Amounts falling due within one year 6 341,612 144,282
NET CURRENT LIABILITIES (177,472 ) (118,910 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(175,623

)

(118,910

)

CAPITAL AND RESERVES
Called up share capital 8 1 1
Retained earnings (175,624 ) (118,911 )
SHAREHOLDERS' FUNDS (175,623 ) (118,910 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 13th September 2024 and were signed by:





B K Haeussler - Director


IGES UK PHARMA CONSULTING LTD (REGISTERED NUMBER: 11905461)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST DECEMBER 2023


1. STATUTORY INFORMATION

IGES UK Pharma Consulting Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The accounts have been prepared on a going concern basis as the parent company has confirmed that they will continue to provide financial support for the foreseeable future and will not seek repayment of the amounts due to them until such time as the company has sufficient resources to do so.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is adjusted for amounts invoiced in advance of the work being undertaken.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on cost

Financial instruments
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


IGES UK PHARMA CONSULTING LTD (REGISTERED NUMBER: 11905461)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST DECEMBER 2023


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 1 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 1,972
At 31st December 2023 1,972
DEPRECIATION
Charge for year 123
At 31st December 2023 123
NET BOOK VALUE
At 31st December 2023 1,849

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Other debtors 52,312 12,707

IGES UK PHARMA CONSULTING LTD (REGISTERED NUMBER: 11905461)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST DECEMBER 2023


6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 11,568 36,582
Amounts owed to group undertakings 290,309 69,102
Taxation and social security 12,488 -
Other creditors 27,247 38,598
341,612 144,282

7. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2023 2022
£    £   
Within one year 24,020 -

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
1,000 Ordinary. 0.1p 1 1

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

David Barr FCA (Senior Statutory Auditor)
for and on behalf of Martin and Company

10. ULTIMATE CONTROLLING PARTY

The company's ultimate holding company is IGES Insitut GmbH. Registered office: Friedrichstrasse 18010117
Berlin Germany.

11. DEFERRED TAX

A deferred tax asset of £23,008 has not been provided for as it is not considered likely that sufficient taxable profits to recover the asset will be generated in the foreseeable future.